Sentences with word «piperaquine»

Resistance to artemisinin in parts of Southeast Asia is well - documented, but until now only a few studies have presented clear evidence of piperaquine resistance.

The findings also provide evidence to initiate surveillance programs to track the spread of piperaquine resistance and clinical trials to test alternative combination therapies.

These findings informed new WHO guidelines reinstating artesunate plus mefloquine as the first - line ACT in Cambodia where dihydroartemisinin - piperaquine treatment has failed.

When multidrug - resistant malaria was detected, researchers were initially handicapped by the lack of a marker for piperaquine resistance; now, they have one, the presence of multiple copies of the plasmepsin 2 gene.

Combined with a relatively new quinoline such as piperaquine — to which resistance is still rare — the drug, or a chemical cousin, might form a cheap and safe new combination therapy, says Kelly.

When piperaquine resistance emerges as well, treatment fails: Patients get better, but a month later they are sick again.

One strain carrying a mutation named C580Y in the K13 gene is pushing out the others; in the process, it has acquired piperaquine resistance as well.

The registration process highlighted concerns that dihydroartemisinin - piperaquine caused some short term changes in electrocardiographs tracing the conduction of the heart rhythm.

Dihydroartemisinin - piperaquine also became one of the few antimalarials to be formally registered by a stringent regulatory authority when the European Medicines Agency approved it for use in 2013.

Additional study findings suggest that artesunate, a form of artemisinin, plus mefloquine, a different long - acting partner drug, should be the first - line ACT in areas where dihydroartemisinin - piperaquine treatment has failed, the study authors note.

«The very long duration of action of piperaquine in this combination, means that DHA - P reduces the risk of the person suffering another bout of malaria for up to nine weeks after treatment,» explained David Sinclair from LSTM.

The superbugs - malaria parasites that can beat off the best current treatments, artemisinin and piperaquine - have spread throughout Cambodia, with even fitter multidrug resistant parasites spreading in southern Laos and northeastern Thailand.

The results of the study, funded by the Malaria Eradication Scientific Alliance (MESA), are published in one of the world's leading medical journals The Lancet Infectious Diseases, and show that adding high doses of ivermectin, an endectocide class of drug, to the antimalarial dihydroartemisinin - piperaquine (DP) had a major and prolonged effect on mosquito mortality.

Now, Pailin is the epicenter of what some say is the greatest threat yet to malaria control: the deadliest malaria parasite, Plasmodium falciparum, has become resistant not only to artemisinin, but to a key partner drug, piperaquine, or PPQ, that is used in combination with artemisinin and is critical to its success.

The researchers showed that they could load two malaria drugs, artesunate and piperaquine, into these polymers.

Malaria experts have been encouraged because so far, parasites resistant to piperaquine are still susceptible to an older drug, mefloquine, that has regained its efficacy after years on the shelf.

Things got worse in 2015, when scientists found that the partner drug used in Cambodia, piperaquine, was failing, too.

The Cambodian government has already switched to an ACT that contains mefloquine instead of piperaquine, and Vietnam is doing the same.

The study, conducted by Victor Bigira and colleagues at San Francisco General Hospital and the Makerere University College of Health Sciences in Kampala, Uganda, finds that treating young children with dihydroartemisinin - piperaquine (DP) decreased their risk of contracting malaria.

Laboratory tests showed the parasites from dihydroartemisinin - piperaquine failures contained a genetic marker of artemisinin resistance and had a decreased susceptibility to piperaquine, demonstrating that both artemisinin and piperaquine resistance contributed to treatment failures.

Dihydroartemisinin - piperaquine is an artemisinin combination therapy (ACT) for malaria that combines potent, fast - acting artemisinin with a long - acting partner drug, piperaquine.

New findings from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), confirm dihydroartemisinin - piperaquine, the first - line treatment for Plasmodium falciparum malaria infection in Cambodia, has failed in certain provinces due to parasite resistance to artemisinin and piperaquine.

NIAID researchers and colleagues sought to confirm the presence of piperaquine - resistant infections in Cambodia by comparing the efficacy of dihydroartemisinin - piperaquine treatment in 204 malaria - afflicted participants aged 2 to 65 years from three provinces in Cambodia with varying levels of artemisinin resistance.

In the new study, the researchers compared this standard of care to a screening approach where pregnant women are tested approximately monthly for malaria using rapid diagnostic tests and treated with a different drug, dihydroartemisinin - piperaquine (DP) only if they test positive for the parasite.

Dihydroartemisinin - piperaquine is one of five artemisinin - based combination therapies currently recommended by the World Health Organization (WHO), and this review finds that it is also one of the most studied.

«Dihydroartemisinin - piperaquine is more effective than artemether - lumefantrine, and has fewer side effects than artesunate - mefloquine» concludes a systematic review published by the Cochrane Infectious Disease Group, hosted by LSTM.

The team of authors from South Africa, Kenya, Geneva and Liverpool included 27 randomized studies, enrolling 16,382 adults and children, which directly compared the relative efficacy and safety of dihydroartemisinin - piperaquine and the widely used alternatives; artemether - lumefantrine, artesunate plus mefloquine, and artesunate plus amodiaquine.

The frontline treatment for uncomplicated malaria in Western Cambodia is the drug combination dihydroartemisinin (DHA)-- piperaquine (PPQ).

This work was carried out in collaboration with the KEMRI - Wellcome Trust Research Programme, and relates to Alexis's longstanding interest in the mechanism of action of antimalarial drugs such as lumefantrine, piperaquine and amodiaquine.